Brief: Cinclus To Start Heealing 1 Phase III Study Of Linaprazan Glurate
29/08/2025 06:35
Aug 29 (Reuters) - Cinclus Pharma Holding publ AB CINPHA.ST: CINCLUS PHARMA TO INITIATE HEEALING 1 PHASE III STUDY OF LINAPRAZAN GLURATE IN PATIENTS WITH EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) STUDY WILL EVALUATE LINAPRAZAN GLURATE FOR TREATMENT OF EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FIRST PATIENT IS EXPECTED TO BE SCREENED IN SEPTEMBER 2025, WITH TOPLINE RESULTS ANTICIPATED IN 2026 Source text: ID:nMFN9tg7Zf Further company coverage: CINPHA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))